Amyris Inc. (AMRS)

7.33
0.23 3.00
NASDAQ : Process Industries
Prev Close 7.56
Open 7.53
Day Low/High 7.16 / 7.72
52 Wk Low/High 2.82 / 9.29
Volume 641.49K
Avg Volume 1.03M
Exchange NASDAQ
Shares Outstanding 64.05M
Market Cap 478.44M
EPS -2.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Amyris, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...

AMRS LOSS NOTICE: Rosen Law Firm Reminds Amyris, Inc. Investors Of The Important Deadline In First Filed Class Action - AMRS

Rosen Law Firm, a global investor rights law firm, reminds purchasers of Amyris, Inc.

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Amyris, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Amyris, Inc.

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Amyris, Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Amyris, Inc.

INVESTOR ALERT: Law Offices Of Howard G. Smith Commences Investigation On Behalf Of Amyris, Inc. Investors

Law Offices of Howard G. Smith announces an investigation on behalf of investors of Amyris, Inc.

INVESTOR ALERT: Goldberg Law PC Announces The Filing Of A Securities Class Action Lawsuit Against Amyris, Inc.

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Amyris, Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Amyris, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Amyris, Inc.

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Amyris, Inc. - AMRS

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of Amyris, Inc.

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Amyris, Inc.

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Amyris, Inc.

Amyris Enables Launch Of New High-Performance Tackifier From Cray Valley Featuring Sustainably-Sourced Resin Technology

Large Market Opportunity for Farnesene-Based Applications

Amyris & Kuraray Deliver Superior Performance In Sumitomo's Dunlop Winter Maxx 02 Car Tires Driving Accelerated Growth For Amyris

Rolling on Liquid Farnesene Rubber Renewable Additive Improves Tire's Ice Grip Performance at Low Temperatures

Biotech Meets Beauty As Biossance™ Announces A New Look And Product Launches

Sustainable Skincare Line Rebrands and Launches at SEPHORA

Amyris Provides Business Update

Mattel CEO Georgiadis Expected to Drive Tech Growth

Mattel CEO Georgiadis Expected to Drive Tech Growth

Mattel's (MAT) naming of former Google president of the Americas Margaret Georgiadis as CEO shows the toy maker wants to make a big splash in the tech world.

Amyris & NIKKOL GROUP Create Leading Cosmetics Ingredient Joint Venture

Amyris & NIKKOL GROUP Create Leading Cosmetics Ingredient Joint Venture

Leading Global Cosmetic Ingredient Innovator Joins Amyris to Accelerate Growth of Leading Cosmetic Skin Care Ingredient Business

Amyris Partners With Queensland To Create The Leading Industrial Biotechnology Hub In Southeast Asia

Amyris Partners With Queensland To Create The Leading Industrial Biotechnology Hub In Southeast Asia

Government and Local Sugarcane Industry Partners with Amyris to Produce Sustainable Ingredients for the Personal Care and Nutraceutical Markets

Amyris Signs Multi-Year Collaboration Extension With Kuraray

Amyris Signs Multi-Year Collaboration Extension With Kuraray

Includes Joint Marketing of Products

Amyris Achieves Key Milestone In Major Drug Discovery Collaboration

Amyris Achieves Key Milestone In Major Drug Discovery Collaboration

Industry Leading µPharm Technology Platform Delivers Initial Development Work in Just Four Months for New Oncology Drug Development

Amyris Reports Third Quarter 2016 Results

Amyris Reports Third Quarter 2016 Results

Record Revenue, Lower SG&A Expenses and Strong Outlook

TheStreet Quant Rating: E+ (Sell)